First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's DiseaseAna Martı́nez, Francisco J. Moreno, Mercedes Alonso et al.|Journal of Medicinal Chemistry|2002Cited by 448
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammationAna Martı́nez, Mercedes Alonso, Ana Castro et al.|Medicinal Research Reviews|2002Cited by 334
Regulation of Inflammatory Response in Neural Cells in Vitro by Thiadiazolidinones Derivatives through Peroxisome Proliferator-activated Receptor γ ActivationRosario Luna‐Medina, Ana Pérez‐Castillo, Marta Cortés‐Canteli et al.|Journal of Biological Chemistry|2005Cited by 196
SAR and 3D-QSAR Studies on Thiadiazolidinone Derivatives: Exploration of Structural Requirements for Glycogen Synthase Kinase 3 InhibitorsAna Martı́nez, Francisco J. Moreno, Isabel Dorronsoro et al.|Journal of Medicinal Chemistry|2005Cited by 128
GSK-3 Inhibitors: Discoveries and DevelopmentsMercedes Alonso, Ana Martı́nez|Current Medicinal Chemistry|2004Cited by 71